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Abstract. The pathobiochemical mechanism of arte­
riosclerosis in hyperhomocysteinaemiu has not yet 
been elucidated. In vitro studies have shown that the 
cytotoxic properties o f homocysteine can be ascribed 
to its generation of reactive oxygen species, We 
studied lipid peroxidation, both in vivo and in vitro, 
in 10 homozygous cystathionine synthase-deficicnt 
(GSD) patients and in a control group of 10 healthy 
subjects o f comparable age and sex. The susceptibility 
of low-density lipoprotein (LDL) from hyperhomo- 
cysteinaemic patients to oxidation was determined in 
vitro by continuously measuring the conjugated diene 
production induced by incubation with copper ions, 
Oxidation resistance (expressed as lag time), maximal 
oxidation rate, and extent o f oxidation (expressed as 
total diene production) of LDL from CSD patients 
were not significantly different from those of LDL 
from controls. Furthermore, the time needed to reach 
maximal diene production, i.e. t(max), was similar lor 
LDL from patients and controls. In addition, the 
vitamin E concentrations in LDL of CSD patients 
and controls were similar. The mean concentration 
(d::SD) o f plasma thiobarbituric acid reactive sub­
stances (TBARS), an indicator of in vivo lipid per­
oxidation, was 2-2 ±  0*7 //mol L 1 in CSD patients, a 
lower value than that measured in the matched con­
trols (5*0 ±  2*0 /¿mol L 1). investigation of in vivo and 
in vitro parameters o f lipid peroxidation shows that 
the increased risk of arteriosclerosis in hyperhomo­
cysteinaemia is unlikely to be due to increased lipid 
peroxidation.
Keywords. Atherosclerosis, cystathionine synthase 
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Introduction
Severe hyperhomocysteinaemia caused by cystathio­
nine synthase deficiency (CSD) is a rare autosomal 
recessive inborn error o f the methionine trans- 
sulphuration pathway. About 50% o f  untreated 
patients suffer from arteriosclerosis or thrombo- 
cmbolisms before 30 years o f age [1], Over tlie. last 
10 years it has become evident that mild hyperhomo- 
cysteinaemia is also an independent risk factor for 
vascular disease [2-8], and very recently it has been 
shown to be a risk factor for obstetric complications 
such as recurrent spontaneous abortion, gross placen­
tal infarcts and neural-tube defects [9,10]. Both severe 
and mild hyperhomocysteinaemia can be effectively 
treated with simple regimens o f vitamin Bfn folate and 
bctaine [3,11]. Mudd at al. [1] were able to demon­
strate that homocysteine-lowering therapy reduced 
the vascular risk of patients with severe hyperhomo­
cysteinaemia due to CSD,
The pathobiochemical mechanism o f  hyperhomo­
cysteinaemia has not yet been elucidated. Endothelial 
damaging effects o f homocysteine have been demon­
strated in vitro and in animal studies (for reviews 
see [3,6,7]). Cultured endothelial cells are damaged by 
exposure to high concentrations o f homocysteine, 
most probably because o f hydrogen peroxide for­
mation [12], Furthermore, other thiol-containing 
amino acids, e.g. cysteine, could induce oxygen radi­
cal production, leading to low density lipoprotein 
(LDL) modification [13]. Oxidative modification o f  
LDL is thought to constitute the link between 
increased plasma cholesterol concentrations and 
atherosclerosis [14-16]. Reactive oxygen species, 
such as superoxide, hydrogen peroxide and the hydro­
xyl radical, can be formed by auto-oxidation o f thiol 
groups [12,13]. Superoxide and hydrogen peroxide are 
relatively benign compared to the highly reactive 
hydroxyl radical. The latter is only generated in the 
presence o f transition metals such as Fe31 and Cu2* 
[17], which is o f  interest with regard to the elevated 
blood levels o f copper and other metals in CSD  
patients [18,19].
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Table 1. Homocysteine and methionine concentrations in plasma 
and homocysteine-lowering therapy in cystathionine ¡3 synthase-
deficient patients
Patient Homocysteine Methionine Therapy
E51 18 24 fija
E53 74 20 b6
U58 16 21 fió, fol
D 66 139 82 B6, fol, bet
D67 222 113 B6, fol, bet
B58 195 82 B6, fol, bet
B61 210 81 Bo, fol, bet
L75 85 57 B6, fol, bet, B12
K61 244 52 No therapy
M62 172 99 b 6
Control (n = 
Mean ±  SD
= 10)
12 dz 2 26 ± 5
Concentrations are expressed as //mol L~*. B^ , 750mg pyridoxinc 
per day administered orally; fol, 5 mg folate per day administered 
orally; bet, 6 g betaine per day administered orally; Bi2) 1 mg 
vitamin B 12 per month administered intramuscularly.
In a previous short communication we reported 
normal concentrations o f malondialdehyde and fluor­
escent lipid peroxidation products in serum of CSD 
patients [20]. The disadvantage o f  using serum for 
measuring lipid peroxidation products has been dis­
cussed previously [21,22]. In the present study, we 
investigated indications of lipid peroxidation in vivo 
and in vitro in EDTA-plasma of hyperhomocysteinae- 
mic CSD patients. To our knowledge, studies on the in 
vitro susceptibility to oxidation of LDL from hyper- 
homocystenaemic patients have not been performed 
before.
Materials and methods
Patients
Homozygosity for CSD was suspected in the 10 
patients (nine males and one female; mean age 
±  SD, 30*1 ±  6*8 years) on the basis of typical clinical 
symptoms such as arteriosclerosis, thrombosis, 
mental retardation, marfanoid features or ectopia 
lentis, and was confirmed biochemically by severe 
hyperhomocysteinaemia and (in most cases) elevated 
methionine and decreased cysteine concentrations in 
plasma, and by very low cystathionine synthase 
activity (<10%  o f  that in controls) in cultured fibro­
blasts. At the time o f  the present investigation, all 
patients but one (K61) were on therapy, which 
included pyridoxine (750 mg daily, administered 
orally) and in some cases folate (5 mg daily, adminis­
tered orally), betaine (5g  daily, administered orally) 
or vitamin B I2 (1 mg per month, administered intra­
muscularly) (Table 1). Due to therapy, two patients 
(E51 and U58) achieved normal homocysteine levels. 
N o other vitamins and no antioxidants were pre­
scribed, and the patients had a normal diet. A control 
group o f 10 healthy subjects (eight males and two
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Figure 1. Kinetics of LDL oxidation as determined by measurement 
of the changc in conjugated dienc absorbance at 234 nm. The 
following indexes o f  LDL oxidizability were determined: dicnc 
production (D minus A), lag time (B)t maximal rate of oxidation 
(C), and t(max), i.e. the time needed to reach maximal diene 
production (E) (from [24]).
females) o f mean age (±  SD) 34*9 ±  6*0 years was 
selected for this study. None of the controls used 
any vitamins or medication. Antecubital venous 
blood samples were collected in the fasting state in 
EDTA-containing vials.
Amino acid analysis
Red cells were separated from the plasma within 
30 min and the plasma was stored at -2 0 °C  until 
analysis. Total homocysteine was measured in EDTA- 
containing plasma as described by Fiskerstrand et a i  
[23], with some minor modifications. Methionine 
concentrations in plasma were measured by ion- 
exchange chromatography on an automatic amino- 
acid analyser (LKB Alpha-plus, Pharmacia, Woer­
den, The Netherlands).
LDL isolation and in vitro oxidation
Plasma was separated within 30 min and stored at 
~80°C in the presence of 6 g saccharose L {. Low- 
density lipoproteins were isolated by a short-run 
ultracentrifugation method and were thereafter 
tested for their susceptibility to in vitro copper- 
induced LDL oxidation [24]. Briefly, after isolation, 
the LDL was dialysed for 24 h in the dark at 4°C 
against phosphate-buffered saline (pH 7-4), contain­
ing 10 /¿mol L r1 EDTA. The buffer was made oxygen- 
free by vacuum degassing followed by purging with 
nitrogen. The LDL-containing sample was filtered 
through a 0*45/um filter and diluted with dialysis 
buffer to a final concentration of 0*05 mg LDL- 
protein mL“1 and 10/¿mol L 1 EDTA. The oxida­
tion was initiated by the addition of a freshly prepared 
solution (15//mol L“1) of copper chloride (C1 1CI2 ). 
The kinetics of LDL oxidation were determined by 
monitoring the change in 234 nm diene absorption on
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a UV-spectrophotometer (Lambda 5, Perkin-Elmer, 
Norwalk, CT, USA), equipped with a six-position 
automatic sample changer, at 30°C The change of 
absorbance at 234 nm vs. time was divided into three 
consecutive phases, i.e. a lag phase, a propagation 
phase and a decomposition phase (Fig. 1). Lag time, 
maximal rate o f oxidation, total amount of conju­
gated dienes formed, and the time needed to reach 
maximal diene production were calculated as described 
previously [24], and despite a small increase in the free 
C1 1CI2 concentration, identical kinetics of LDL oxida­
tion were observed [24],
In vivo lipid peroxidation
The content o f thiobarbituric acid reactive substances 
(TBARS), mainly malondialdehyde (MDA), in 
plasma was measured by recording the fluorescence 
spectrum of the thiobarbituric acid-MDA complex 
between 500 and 600 nm on a Shimadzu RFF-500 
fluorescence detector (Shimadzu Corporation, Kyoto, 
Japan), keeping a constant interval o f 14 nm between 
excitation and emission wavelengths. The fluorescence 
intensity was measured at 553 nm after subtracting the 
baseline value (due to the Rayleigh diffusion). This 
synchronous fluorescence method was found to be 
free from interfering compounds [25].
Other methods
Cholesterol and triglyceride concentrations in plasma 
were determined by enzymatic methods (Boehringer- 
Mannheim, Mannheim, Germany). Plasma HDL- 
cholesterol was determined by the polyethylene- 
glycol 6000 method [26], LDL-cholesterol in plasma 
was calculated by subtracting the sum of HDL- 
cholesterol and 0-42 x triglycerides from total 
plasma cholesterol.
The vitamin E concentrations in LDL were deter­
mined by high performance liquid chromatography 
(HPLC) as described previously [27]. LDL fatty acid 
composition was measured as described previously 
[27], and was expressed as a percentage of total fatty
n /i
1 7  4
Statistical analysis
The results are expressed as mean values ±SD *  
Statistical evaluation of the data was performed 
using Student’s Mest. Pearson correlation coeffi­
cients were computed to determine correlations 
between homocysteine concentrations and oxidation 
parameters. A two-tailed P-value of less than 0*05 was 
considered to be statistically significant.
Results
of total homocysteine concentrations in plasma, from 
virtually normal levels up to 244//,m olL~1 (Table 1). 
The mean total homocysteine concentration (±  SD) in 
plasma o f the control group was 1 2 ± 2 //m o lL '~ 1. 
Plasma methionine levels in the patient group 
ranged from 20 to 161/zm olL“ 1, and the mean 
concentration (± S D ) for the control group was 
26 ±  5 /zmolLT1.
Plasma lipids and f a t t y  acid composition o f  L D L
Plasma total cholesterol (5-2 ±  1*0 mmol L“ 1), tri­
glycerides (0-93 ±  0-41 mmol L~l), LDL-cliolesterol 
(3*33 ±  1 *01 mmol L” 1) and HDL-cholesterol (1*31 ±  
0*23 mmol L"1) concentrations in the hyperhomo- 
cysteinaemic patients were all normal [28]. In the 
control group the total cholesterol concentration 
was 6*0 ±2*1 m m olL ” 1 and the triglyceride concen­
tration was 0*99 ±  0-40 mmol L” 1.
The fatty acid composition o f LDL in the hyperho- 
mocysteinaemic patients was also normal: arachi- 
donic acid (20:4), 5*1 ±  1*2%; linoleic acid (18:2). 
40*2 ±4*9%; oelic acid (18:1), 2 M  ±3*4%; stearic 
acid (18:0), 9*0 ±3*3%; and palmitic acid (16:0), 
24*5 ±  1*3%. Control values were as follows: arachi- 
donic acid (20:4), 6-2 ±1*4%; linoleic acid (18:2), 
40*0 ±3-7%; oleic acid (18:1), 19*3 ±3*0% ; stearic 
acid (18:0), 8*4 ±1*8%; and palmitic acid (16:0), 
26*1 ±2*3%.
Susceptibility to oxidation o f  low-density lipoprotein 
and L D L  vitamin E content
The susceptibility to oxidation o f LDL from hyper- 
homocysteinaemic patients was determined in vitro by 
continuously measuring the conjugated diene produc­
tion induced by incubation with copper (Fig. 1). 
Oxidation resistance (expressed as lag time), maximal 
oxidation rate, and extent o f oxidation (expressed as 
total diene production) o f LDL from CSD patients 
were not significantly different from control values 
(Table 2). In addition, the time taken to reach max­
imal diene production, t(max), was similar for LDL  
from patients and controls. N o  correlations were 
observed between plasma homocysteine concentra­
tions and biochemical LDL oxidizability indexes.
The vitamin E content o f LDL was also deter­
mined, since vitamin E is quantitatively and qualita­
tively the most important endogenous antioxidant in 
LDL, Decreased levels o f vitamin E might be indica­
tive o f increased in vivo exposure to oxidative stress. 
However, the vitamin E concentrations of LDL did 
not differ significantly between controls and CSD  
patients (Table 2). N o  significant correlation was 
observed between the concentration o f  vitamin E in 
LDL and the plasma homocysteine concentration.
Plasma homocysteine and methionine
The homozygous CSD patients exhibited a wide range
Lipid peroxidation
TBARS are products o f  peroxidation o f  unsaturated
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Table 2. Individual iow-density lipoprotein (LDL) oxidizability indexes and LDL vitamin E concentrations in
cystathionine synthase-deficient patients and controls
Patient
number
Lag time 
(min)
Oxidation rate 
(nmol min” 1 mg 
LDL-protein)
-i
Diene production 
(nmol mg“'1)
LDL-protein)
t(max)
(min)
Vitamin E
(m gg~‘)
LDL-protein)
E5l 133 11*75 654 213 5*32
E53 125 8*81 528 210 5*92
U58 112 9*49 464 183 4*29
D 66 134 9*72 533 213 4*70
D67 126 9*27 532 207 4-93
B58 133 5’20 297 204 2*91
B61 121 5*88 292 192 3-04
L75 148 9-49 574 237 5*59
K61 119 10*62 580 198 5-06
M 6Î 141 9-04 536 225 5-81
Mean 129 8*9 499 208 4*76
SD 9 2*0 118 17 1-06
Control (n =  10) 129 9*8 540 209 4*04
(« =  10) 
SD 16 1*9 68 21 1*34
fatty acids. The mean plasma TBARS concentration 
(=h SD) in CSD patients was 2*2 ±  0*7 /¿mol (n = 1 1 ) ,  
The TBARS concentration in the matched controls
was significantly higher (5’0 ± 2 '0 //m o IL  , /* =  12, 
P  <  0 001). N o significant correlation was observed 
between the concentrations of homocysteine and 
TBARS in plasma of the hyperhomocysteinaemic 
patients.
Discussion
The susceptibility to in vitro oxidation of LDL from 
patients with hyperhomocysteinaemia due to CSD 
was not increased compared to that of LDL from 
controls. Furthermore, the LDL vitamin E content 
was not decreased in these CSD patients, and the 
plasma TBARS concentration, indicative of in vivo 
lipid peroxidation, was even lower in the CSD patients 
than in controls. Even in patients with very high 
homocysteine concentrations (patients D67, B61 and 
K61), LDL oxidizability and plasma TBARS concen­
tration were not increased, and the vitamin E content 
of LDL was not decreased. These data are in agree­
ment with our previous data on malondialdehyde and 
fluorescent lipid peroxidation products in the serum 
of hyperhomocysteinaemic patients [20], and argue 
against the view that lipid peroxidation acts as a 
mediator in the vascular damaging effect o f homo­
cysteine. Many in vitro studies (for reviews, see [3,6,7]) 
have described endothelial damaging properties of 
homocysteine mediated through the production of 
reactive oxygen species. In virtually all o f these 
studies, applied very high and non-physiological con­
centrations o f 1 to 10 mM homocysteine, i.e. the 
reduced form. This is extremely unphysiological 
because almost all homocysteine in the blood is 
present in its oxidized disulphide form, either as 
homocystine or in combination with other thiol-
group-containing biomolccules, such as cysteine and 
proteins. Homocysteine in its reduced form is only 
present in small amounts (typically 1 % or even less of 
the total pool o f homocysteine present in the blood
[29]), which argues against homocysteine-mediated 
lipid peroxidation in hyperhomocysteinacmia. Our 
observation that plasma TBARS concentrations are 
even decreased in hyperhomocysteinaemic patients is 
in agreement with the recent findings of Dudman et al.
[30]. They also reported in CSD patients decreased 
concentrations of lipid peroxidation products, in their 
case reduced levels o f high-density lipoprotein choles- 
teryl ester hydroperoxides, and an elevated ubiquinol- 
lO/ubiquinone-lO ratio, Taking these results together, 
it seems unlikely that hyperhomocysteinaemia induces 
lipid peroxidation in the bloodstream of CSD 
patients.
Amino acids or peptides with a free thiol moiety, 
including cysteine and glutathione, are able to gen­
erate reactive oxygen species through an auto-oxida­
tion process [31], Thiol auto-oxidation is likely to 
occur in the presence of trace amounts o f Fe3f or 
Cu24, resulting in a Fenton-type reaction, with 
ensuing radical production [17]. Despite this, thiol 
compounds are not known to cause vascular 
damage in vivo. Compounds with a free thiol func­
tion, such as N-acetylcysteine and other glutathione 
precursors, are even thought to increase glutathione 
concentrations, thereby providing increased avail­
ability o f the substrate for the intracellular enzyme 
glutathione peroxidase, which detoxifies hydrogen 
peroxide and lipid peroxides [32], Clearly, thiol func­
tions have ambivalent characteristics with regard to 
scavenging and generation of reactive oxygen species, 
as we have recently shown for N-acetyleysteine [33].
The absence of a correlation between plasma 
homocysteine concentration and indices o f  lipid per­
oxidation suggests that other pathobiochemical
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mechanisms are responsible for the association 
between hyperhomocysteinaemia and atherosclero­
sis. The enhanced binding of lipoprotein(a) to fibrin, 
induced by sulphydryl compounds, including homo­
cysteine, might be an alternative explanation linking 
thrombosis and atherosclerosis with hyperhomo­
cysteinaemia [34]. Also intriguing are the recently 
described effects of homocysteine on the endothelium- 
derived relaxing factor nitric oxide [35], and the 
relationship between homocysteine and disturbance 
of fibrinolysis [36].
In conclusion, although several parameters of lipid 
peroxidation, both in vivo and in vitro, were measured, 
no evidence was obtained that the increased risk of' 
arteriosclerosis in hyperhomocysteinaemia can be 
explained by increased lipid peroxidation. It seems 
more likely that another mechanism, unrelated to 
lipid peroxidation, is involved in vascular disease 
due to hyperhomocysteinaemia.
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Abstract. The palhobiochemical mechanism of arte­
riosclerosis in hyperhomocysteinacmiu has not yet 
been elucidated. In vitro studies have shown that the 
cytotoxic properties o f homocysteine can be ascribed 
to its generation of reactive oxygen species, We 
studied lipid peroxidation, both in vivo and in vitro, 
in 10 homozygous cystathionine synthase-deiicicnt 
(GSD) patients and in a control group of 10 healthy 
subjects o f comparable age and sex. The susceptibility 
of low-density lipoprotein (LDL) from hyperhomo- 
cysteinaemic patients to oxidation was determined in 
vitro by continuously measuring the conjugated diene 
production induced by incubation with copper ions, 
Oxidation resistance (expressed as lag time), maximal 
oxidation rate, and extent o f oxidation (expressed as 
total diene production) of LDL from CSD patients 
were not significantly diilerent from those of LDL 
from controls. Furthermore, the time needed to reach 
maximal diene production, i.e. t(max), was similar for 
LDL from patients and controls. In addition, the 
vitamin E concentrations in LDL of CSD patients 
and controls were similar. The mean concentration 
(d::SD) o f plasma thiobarbituric acid reactive sub­
stances (TBARS), an indicator of in vivo lipid per­
oxidation, was 2-2 ±  0*7 //mol L 1 in CSD patients, a 
lower value than that measured in the matched con­
trols (5*0 db 2'0 /¿mol L 1). investigation of in vivo and 
in vitro parameters o f lipid peroxidation shows that 
the increased risk of arteriosclerosis in hyperhomo­
cysteinaemia is unlikely to be due to increased lipid 
peroxidation.
Keywords. Atherosclerosis, cystathionine synthase 
deficiency, hyperhomocysteinaemia, lipid peroxi­
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Introduction
Severe hyperhomocysteinaemia caused by cystathio­
nine synthase deficiency (CSD) is a rare autosomal 
recessivc inborn error o f the methionine trans- 
sulphuration pathway. About 50% o f  untreated 
patients suffer from arteriosclerosis or thrombo- 
embolisms before 30 years o f age [1], Over tlie. last 
10 years it has become evident that mild hyperhomo- 
eysteinacmia is also an independent risk factor for 
vascular disease [2-8], and very recently it has been 
shown to be a risk factor for obstetric complications 
such as recurrent spontaneous abortion, gross placen­
tal infarcts and neural-tube defects [9,10]. Both severe 
and mild hyperhomocysteinaemia can be effectively 
treated with simple regimens o f vitamin Bfn folate and 
bctaine [3,11]. Mudd at al. [1] were able to demon­
strate that homocysteine-lowering therapy reduced 
the vascular risk of patients with severe hyperhomo­
cysteinaemia due to CSD,
The pathobiochemical mechanism o f  hyperhomo­
cysteinaemia has not yet been elucidated. Endothelial 
damaging effects o f homocysteine have been demon­
strated in vitro and in animal studies (for reviews 
see [3,6,7]). Cultured endothelial cells are damaged by 
exposure to high concentrations o f homocysteine, 
most probably because o f hydrogen peroxide for­
mation [12], Furthermore, other thiol-containing 
amino acids, e.g. cysteine, could induce oxygen radi­
cal production, leading to low density lipoprotein 
(LDL) modification [13]. Oxidative modification o f  
LDL is thought to constitute the link between 
increased plasma cholesterol concentrations and 
atherosclerosis [14-16]. Reactive oxygen species, 
such as superoxide, hydrogen peroxide and the hydro­
xyl radical, can be formed by auto-oxidation o f thiol 
groups [12,13]. Superoxide and hydrogen peroxide are 
relatively benign compared to the highly reactive 
hydroxyl radical. The latter is only generated in the 
presence o f transition metals such as Fe31 and Cu2* 
[17], which is o f  interest with regard to the elevated 
blood levels o f copper and other metals in CSD  
patients [18,19].
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Table 1. Homocysteine and methionine concentrations in plasma 
and homocysteine-lowering therapy in cystathionine ¡3 synthase-
deficient patients
Patient Homocysteine Methionine Therapy
E51 18 24 fija
E53 74 20 b6
U58 16 21 fió, fol
D 66 139 82 B6, fol, bet
D67 222 113 B6, fol, bet
B58 195 82 B6, fol, bet
B61 210 81 Bo, fol, bet
L75 85 57 B6, fol, bet, B12
K61 244 52 No therapy
M62 172 99 b 6
Control (n = 
Mean ±  SD
= 10)
12 dz 2 26 ± 5
Concentrations are expressed as //mol L~*. B^ , 750mg pyridoxinc 
per day administered orally; fol, 5 mg folate per day administered 
orally; bet, 6 g betaine per day administered orally; Bi2) 1 mg 
vitamin B 12 per month administered intramuscularly.
In a previous short communication we reported 
normal concentrations o f malondialdehyde and fluor­
escent lipid peroxidation products in serum of CSD 
patients [20]. The disadvantage o f  using serum for 
measuring lipid peroxidation products has been dis­
cussed previously [21,22]. In the present study, we 
investigated indications of lipid peroxidation in vivo 
and in vitro in EDTA-plasma of hyperhomocysteinae- 
mic CSD patients. To our knowledge, studies on the in 
vitro susceptibility to oxidation of LDL from hyper- 
homocystenaemic patients have not been performed 
before.
Materials and methods
Patients
Homozygosity for CSD was suspected in the 10 
patients (nine males and one female; mean age 
±  SD, 30*1 ±  6*8 years) on the basis of typical clinical 
symptoms such as arteriosclerosis, thrombosis, 
mental retardation, marfanoid features or ectopia 
lentis, and was confirmed biochemically by severe 
hyperhomocysteinaemia and (in most cases) elevated 
methionine and decreased cysteine concentrations in 
plasma, and by very low cystathionine synthase 
activity (<10%  o f  that in controls) in cultured fibro­
blasts. At the time o f  the present investigation, all 
patients but one (K61) were on therapy, which 
included pyridoxine (750 mg daily, administered 
orally) and in some cases folate (5 mg daily, adminis­
tered orally), betaine (5g  daily, administered orally) 
or vitamin B I2 (1 mg per month, administered intra­
muscularly) (Table 1). Due to therapy, two patients 
(E51 and U58) achieved normal homocysteine levels. 
N o other vitamins and no antioxidants were pre­
scribed, and the patients had a normal diet. A control 
group o f 10 healthy subjects (eight males and two
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Figure 1. Kinetics of LDL oxidation as determined by measurement 
of the changc in conjugated dienc absorbance at 234 nm. The 
following indexes o f  LDL oxidizability were determined: dicnc 
production (D minus A), lag time (B)t maximal rate of oxidation 
(C), and t(max), i.e. the time needed to reach maximal diene 
production (E) (from [24]).
females) o f mean age (±  SD) 34*9 ±  6*0 years was 
selected for this study. None of the controls used 
any vitamins or medication. Antecubital venous 
blood samples were collected in the fasting state in 
EDTA-containing vials.
Amino acid analysis
Red cells were separated from the plasma within 
30 min and the plasma was stored at -2 0 °C  until 
analysis. Total homocysteine was measured in EDTA- 
containing plasma as described by Fiskerstrand et a i  
[23], with some minor modifications. Methionine 
concentrations in plasma were measured by ion- 
exchange chromatography on an automatic amino- 
acid analyser (LKB Alpha-plus, Pharmacia, Woer­
den, The Netherlands).
LDL isolation and in vitro oxidation
Plasma was separated within 30 min and stored at 
~80°C in the presence of 6 g saccharose L {. Low- 
density lipoproteins were isolated by a short-run 
ultracentrifugation method and were thereafter 
tested for their susceptibility to in vitro copper- 
induced LDL oxidation [24]. Briefly, after isolation, 
the LDL was dialysed for 24 h in the dark at 4°C 
against phosphate-buffered saline (pH 7-4), contain­
ing 10 /¿mol L r1 EDTA. The buffer was made oxygen- 
free by vacuum degassing followed by purging with 
nitrogen. The LDL-containing sample was filtered 
through a 0*45 ¿im filter and diluted with dialysis 
buffer to a final concentration of 0*05 mg LDL- 
protein mL“1 and 10/¿mol L 1 EDTA. The oxida­
tion was initiated by the addition of a freshly prepared 
solution (15//mol L“1) of copper chloride (C1 1CI2 ). 
The kinetics of LDL oxidation were determined by 
monitoring the change in 234 nm diene absorption on
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a UV-spectrophotometer (Lambda 5, Perkin-Elmer, 
Norwalk, CT, USA), equipped with a six-position 
automatic sample changer, at 30°C The change of 
absorbance at 234 nm vs. time was divided into three 
consecutive phases, i.e. a lag phase, a propagation 
phase and a decomposition phase (Fig. 1). Lag time, 
maximal rate o f oxidation, total amount of conju­
gated dienes formed, and the time needed to reach 
maximal diene production were calculated as described 
previously [24], and despite a small increase in the free 
CuCl2 concentration, identical kinetics of LDL oxida­
tion were observed [24],
In vivo lipid peroxidation
The content o f thiobarbituric acid reactive substances 
(TBARS), mainly malondialdehyde (MDA), in 
plasma was measured by recording the fluorescence 
spectrum of the thiobarbituric acid-MDA complex 
between 500 and 600 nm on a Shimadzu RFF-500 
fluorescence detector (Shimadzu Corporation, Kyoto, 
Japan), keeping a constant interval o f 14 nm between 
excitation and emission wavelengths. The fluorescence 
intensity was measured at 553 nm after subtracting the 
baseline value (due to the Rayleigh diffusion). This 
synchronous fluorescence method was found to be 
free from interfering compounds [25].
Other methods
Cholesterol and triglyceride concentrations in plasma 
were determined by enzymatic methods (Boehringer- 
Mannheim, Mannheim, Germany). Plasma HDL- 
cholesterol was determined by the polyethylene- 
glycol 6000 method [26], LDL-cholesterol in plasma 
was calculated by subtracting the sum of HDL- 
cholesterol and 0-42 x triglycerides from total 
plasma cholesterol.
The vitamin E concentrations in LDL were deter­
mined by high performance liquid chromatography 
(HPLC) as described previously [27]. LDL fatty acid 
composition was measured as described previously
[27], and was expressed as a percentage of total fatty
n /i
1 7  4
Statistical analysis
The results are expressed as mean values ±SD *  
Statistical evaluation of the data was performed 
using Student’s Mest. Pearson correlation coeffi­
cients were computed to determine correlations 
between homocysteine concentrations and oxidation 
parameters. A two-tailed P-value of less than 0*05 was 
considered to be statistically significant.
Results
of total homocysteine concentrations in plasma, from 
virtually normal levels up to 244//,m olL~1 (Table 1). 
The mean total homocysteine concentration (±  SD) in 
plasma o f the control group was 1 2 ± 2 //m o lL '~ 1. 
Plasma methionine levels in the patient group 
ranged from 20 to 161/zm olL“ 1, and the mean 
concentration (± S D ) for the control group was 
26 ±  5 /xmolL"1.
Plasma lipids and f a t t y  acid composition o f  L D L
Plasma total cholesterol (5-2 ±  1*0 mmol L“ 1), tri­
glycerides (0-93 ±  0-41 mmol L~l), LDL-cholesterol 
(3*33 ±  1 *01 mmol L” 1) and HDL-cholesterol (1*31 ±  
0*23 mmol L"1) concentrations in the hyperhomo- 
cysteinaemic patients were all normal [28]. In the 
control group the total cholesterol concentration 
was 6*0 ±2*1 m m olL ” 1 and the triglyceride concen­
tration was 0*99 ±  0-40 mmol L” 1.
The fatty acid composition o f LDL in the hyperho- 
mocysteinaemic patients was also normal: arachi- 
donic acid (20:4), 5*1 ±  1*2%; linoleic acid (18:2). 
40*2 ±4*9%; oelic acid (18:1), 2 M  ±3*4%; stearic 
acid (18:0), 9*0 ±3*3%; and palmitic acid (16:0), 
24*5 ±  1*3%. Control values were as follows: arachi- 
donic acid (20:4), 6-2 ±1*4%; linoleic acid (18:2), 
40*0 ±3-7%; oleic acid (18:1), 19*3 ±3*0% ; stearic 
acid (18:0), 8*4 ±1*8%; and palmitic acid (16:0), 
26*1 ±2*3%.
Susceptibility to oxidation o f  low-density lipoprotein 
and L D L  vitamin E content
The susceptibility to oxidation o f LDL from hyper- 
homocysteinaemic patients was determined in vitro by 
continuously measuring the conjugated diene produc­
tion induced by incubation with copper (Fig. 1). 
Oxidation resistance (expressed as lag time), maximal 
oxidation rate, and extent o f oxidation (expressed as 
total diene production) o f LDL from CSD patients 
were not significantly difFerent from control values 
(Table 2). In addition, the time taken to reach max­
imal diene production, t(max), was similar for LDL  
from patients and controls. N o  correlations were 
observed between plasma homocysteine concentra­
tions and biochemical LDL oxidizability indexes.
The vitamin E content o f LDL was also deter­
mined, since vitamin E is quantitatively and qualita­
tively the most important endogenous antioxidant in 
LDL, Decreased levels o f vitamin E might be indica­
tive o f increased in vivo exposure to oxidative stress. 
However, the vitamin E concentrations of LDL did 
not differ significantly between controls and CSD  
patients (Table 2). N o  significant correlation was 
observed between the concentration o f  vitamin E in 
LDL and the plasma homocysteine concentration.
Plasma homocysteine and methionine
The homozygous CSD patients exhibited a wide range
Lipid peroxidation
TBARS are products o f  peroxidation o f  unsaturated
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Table 2. Individual low-density lipoprotein (LDL) oxidizability indexes and LDL vitamin E concentrations in
cystathionine synthase-deficient patients and controls
Patient
number
Lag time 
(min)
Oxidation rate 
(nmol min” 1 mg 
LDL-protein)
-i
Diene production 
(nmol mg“'1)
LDL-protein)
t(max)
(min)
Vitamin E
(m gg~‘)
LDL-protein)
E5l 133 11*75 654 213 5*32
E53 125 8*81 528 210 5*92
U58 112 9*49 464 183 4*29
D 66 134 9*72 533 213 4*70
D67 126 9*27 532 207 4-93
B58 133 5’20 297 204 2*91
B61 121 5*88 292 192 3-04
L75 148 9-49 574 237 5*59
K61 119 10*62 580 198 5-06
M 6Î 141 9-04 536 225 5-81
Mean 129 8*9 499 208 4*76
SD 9 2*0 118 17 1-06
Control (n =  10) 129 9*8 540 209 4*04
(« =  10) 
SD 16 1*9 68 21 1*34
fatty acids. The mean plasma TBARS concentration 
(=h SD) in CSD patients was 2*2 ±  0*7 /¿mol (n = 1 1 ) ,  
The TBARS concentration in the matched controls
was significantly higher (5 * 0 ± 2 '0 //m o IL " , /* =  12, 
P  <  0 001). N o significant correlation was observed 
between the concentrations of homocysteine and 
TBARS in plasma of the hyperhomocysteinaemic 
patients.
Discussion
The susceptibility to in vitro oxidation of LDL from 
patients with hyperhomocysteinaemia due to CSD 
was not increased compared to that of LDL from 
controls. Furthermore, the LDL vitamin E content 
was not decreased in these CSD patients, and the 
plasma TBARS concentration, indicative of in vivo 
lipid peroxidation, was even lower in the CSD patients 
than in controls. Even in patients with very high 
homocysteine concentrations (patients D67, B61 and 
K61), LDL oxidizability and plasma TBARS concen­
tration were not increased, and the vitamin E content 
of LDL was not decreased. These data are in agree­
ment with our previous data on malondialdehyde and 
fluorescent lipid peroxidation products in the serum 
of hyperhomocysteinaemic patients [20], and argue 
against the view that lipid peroxidation acts as a 
mediator in the vascular damaging effect o f homo- 
cysteine. Many in vitro studies (for reviews, see [3,6,7]) 
have described endothelial damaging properties of 
homocysteine mediated through the production of 
reactive oxygen species. In virtually all o f these 
studies, applied very high and non-physiological con­
centrations o f 1 to 10 mM homocysteine, i.e. the 
reduced form. This is extremely unphysiological 
because almost all homocysteine in the blood is 
present in its oxidized disulphide form, either as 
homocystine or in combination with other thiol-
group-containing biomolccules, such as cysteine and 
proteins. Homocysteine in its reduced form is only 
present in small amounts (typically 1 % or even less of 
the total pool o f homocysteine present in the blood
[29]), which argues against homocysteine-mediated 
lipid peroxidation in hyperhomocysteinacmia. Our 
observation that plasma TBARS concentrations are 
even decreased in hyperhomocysteinaemic patients is 
in agreement with the recent findings of Dudman et al.
[30]. They also reported in CSD patients decreased 
concentrations of lipid peroxidation products, in their 
case reduced levels o f high-density lipoprotein choles- 
teryl ester hydroperoxides, and an elevated ubiquinol- 
lO/ubiquinone-lO ratio, Taking these results together, 
it seems unlikely that hyperhomocysteinaemia induces 
lipid peroxidation in the bloodstream of CSD 
patients.
Amino acids or peptides with a free thiol moiety, 
including cysteine and glutathione, are able to gen­
erate reactive oxygen species through an auto-oxida­
tion process [31], Thiol auto-oxidation is likely to 
occur in the presence of trace amounts o f Fe3f or 
Cu24, resulting in a Fenton-type reaction, with 
ensuing radical production [17]. Despite this, thiol 
compounds are not known to cause vascular 
damage in vivo. Compounds with a free thiol func­
tion, such as N-acetylcysteine and other glutathione 
precursors, are even thought to increase glutathione 
concentrations, thereby providing increased avail­
ability o f the substrate for the intracellular enzyme 
glutathione peroxidase, which detoxifies hydrogen 
peroxide and lipid peroxides [32], Clearly, thiol func­
tions have ambivalent characteristics with regard to 
scavenging and generation of reactive oxygen species, 
as we have recently shown for N-acetyleysteine [33].
The absence of a correlation between plasma 
homocysteine concentration and indices o f  lipid per­
oxidation suggests that other pathobiochemical
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mechanisms are responsible for the association 
between hyperhomocysteinaemia and atherosclero­
sis. The enhanced binding of lipoprotein(a) to fibrin, 
induced by sulphydryl compounds, including homo­
cysteine, might be an alternative explanation linking 
thrombosis and atherosclerosis with hyperhomo­
cysteinaemia [34]. Also intriguing are the recently 
described effects of homocysteine on the endothelium- 
derived relaxing factor nitric oxide [35], and the 
relationship between homocysteine and disturbance 
of fibrinolysis [36].
In conclusion, although several parameters of lipid 
peroxidation, both in vivo and in vitro, were measured, 
no evidence was obtained that the increased risk of' 
arteriosclerosis in hyperhomocysteinaemia can be 
explained by increased lipid peroxidation. It seems 
more likely that another mechanism, unrelated to 
lipid peroxidation, is involved in vascular disease 
due to hyperhomocysteinaemia.
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